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Abstract
Background: Most cancer patients still die in hospital, mainly in medical wards. Many studies in different countries
have shown the poor quality of end-of-life care delivery in hospitals. The Program “Liverpool Care Pathway for the
dying patient” (LCP), developed in the UK to transfer the hospice model of care into hospitals and other care
settings, is a complex intervention to improve the quality of end-of-life care. The results from qualitative and
quantitative studies suggest that the LCP Program can improve significantly the quality of end-of-life care delivery
in hospitals, but no randomised trial has been conducted till now.
Methods and design: This is a randomized cluster trial, stratified by regions and matched for assessment period.
Pairs of eligible medical wards from different hospitals will be randomized to receive the LCP-I Program or no
intervention until the end of the trial. The LCP-I Program will be implemented by a Palliative Care Unit.
The assessment of the end-points will be performed for all cancer deaths occurred in the six months after the end
of the LCP-I implementation in the experimental wards and, in the same period of time, in the matched control
wards. The primary end-point is the overall quality of end-of-life care provided on the ward to dying cancer
patients and their families, assessed using the Global Scale of the Italian version of the Toolkit “After-death Bereaved
Family Member Interview“.
Discussion: This study can be interpreted as a Phase III trial according to the Medical Research Council Framework.
In this study, the effectiveness of a fully defined intervention is assessed by comparing the distribution of the
endpoints in the experimental and in the control arm.
Research ID: RFPS-2006-6-341619
Trial registration: ClinicalTrials.gov Identifier: NCT01081899
Background
Despite the development of palliative care services
worldwide [1] and numerous studies showing that most
cancer patients would prefer to die at home [2,3], most
cancer patients still die in hospital [3,4]. Official Italian
statistics on place of death are not available for Italy,
but according to ISDOC survey [3], it is estimated that
one third (34.6%) of cancer patients die in hospital, with
broad geographical differences (from 60.2% in the North
East to 4.6% in the South and islands). According to the
I S D O Cs u r v e yi ti sa l s op o s s i b l et oe s t i m a t et h a ta b o u t
50% of all hospital cancer deaths occur on medical
wards [3].
A number of studies carried out in different countries
[5-8] have shown the poor quality of end-of-life care
delivery in hospitals. Inappropriate end-of-life care may
result in the continuation of invasive treatments that, in
addition to having negative consequences in terms of
resource management, negatively impact the quality of
life of patients [9,10]. The results of two Italian studies
conducted in patients who died in hospital from cancer
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observed for other countries [11,12].
Since the second half of the 90 s, research groups in
the UK and the USA, have developed, implemented and
started to evaluate the effect of the introduction of
“Care Pathway” for end-of-life care in hospitals [13-15].
The aim of these programs was to introduce the skills
necessary to address the complex needs of dying
patients and their families into the hospital setting, in
an attempt to transfer the “hospice expertise” into a
non-specialist context.
A “Care Pathway” is a set of evidence-based, medical
and care practices aimed at specific groups of patients.
The Care Pathway defines the expected course of events
in patient care on an established timeline. Care path-
ways documentation becomes an integral part of the
clinical documentation and allows outcomes assessment
[16]. In the healthcare setting, Care Pathways have
proved to be useful in improving efficiency and effec-
tiveness of the process of care for various pathologies
[17].
Among the different Care Pathways proposed at inter-
national level, the most structured and proficient seems
to be the “Liverpool Care Pathway for the dying patient”
(LCP) [13]. Developed in the UK to transfer the hospice
model of care into hospitals and other care settings, it is
currently in use in over 20 countries [18]. The imple-
mentation of the LCP Program, after an intensive train-
ing phase, revolves around the introduction of the LCP
medical chart and other specific documentation for
patients who have been assessed by a multidisciplinary
team to be at the end of their life. The LCP documenta-
tion provides recommendations on different aspects of
care including comfort measures, anticipatory prescrip-
tion of medication and the assessment of nonessential
medical treatments. It also provides guidance for the
psychological and spiritual support of patients and their
families. The LCP documentation allows the monitoring
of results and supports the implementation of audit
procedures.
The Italian version of the LCP - Un percorso integrato
p e rl ec u r ed if i n ev i t ai no s p e d a l e( L C P - I )-h a sb e e n
developed by the Regional Palliative Care Network of
the National Cancer Research Institute of Genoa (Italy)
in compliance with the original format. The final version
has been endorsed by the Central Team UK, Marie
Curie Palliative Care Institute Liverpool (MCPCIL).
In Italy, the LCP-I Program has been successfully
p i l o t e di n2 0 0 7i nt h eM e d i c a lW a r do f“Villa Scassi
Hospital” in Genoa. The implementation process has
been evaluated using a combined qualitative and quanti-
tative approach. Focus groups, performed on sample of
doctors and nurses before and after the implementation
of the LCP-I, showed a perception of effectiveness of
the Program, particularly in pain management and in
communication with patients and their families.
The availability of an effective quality improvement
program for the care of dying patients in hospitals is
particularly relevant to the healthcare scenario. The
LCP-I Program has provided enough evidence to justify
a randomized trial to evaluate its effectiveness. Although
the core objective of the LCP-I is improving the quality
of end of life care for dying patients, the Program tar-
gets the healthcare professionals working on the hospital
ward. The only feasible method of assessing the effec-
tiveness of this Program is by performing a cluster trial,
where hospital wards are randomized to receive (or not
to receive) the implementation of the LCP-I Program.
Methods/Design
Study design
This is a randomized cluster trial, stratified by regions
and matched for assessment period. Pairs of eligible
medical wards from different hospitals will be rando-
mized to receive the experimental intervention (the
LCP-I Program) or no intervention until the end of the
trial (Figure 1). In each experimental ward, the LCP-I
Program will be implemented by a Palliative Care Unit
(PCU) responsible for the implementation of the Pro-
gram on the ward.
Primary aim
To evaluate the effectiveness of the LCP-I Program in
improving the quality of end-of-life care provided to
cancer patients who die on hospital medical wards as
compared to standard healthcare practices.
Secondary aims
To evaluate the effectiveness of the LCP-I Program in
terms of:
￿ quality of communication between the healthcare
professionals, patients and families;
￿ quality of emotional support to family members
before and after the patients’ death;
￿ coordination of care;
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Figure 1 Selection and matching of pairs of wards
participating to the trial.
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Page 2 of 10￿ provision of care focusing on patient’si n d i v i d u a l
needs;
￿ patient’s physical well-being through a better con-
trol of physical symptoms;
￿ appropriateness of therapeutic and diagnostic pro-
cedures performed during the last days of the
patient’s life;
￿ quality of communication between hospital staff
and General Practitioners (GPs).
General procedures of the cluster trial
Pairs of eligible medical wards from different hospitals
will be randomized to receive the experimental interven-
tion (the LCP-I Program) or no intervention at all for
the duration of the study (Figure 2). To avoid the risk of
contamination, each hospital will be allowed to select
only one eligible ward.
Immediately after randomization the PCU responsible
for LCP-I implementation on the experimental ward will
complete, as quickly as possible, all the organizational
procedures required for the implementation of the Pro-
gram. At the same time the Regional Coordination
Structure will start baseline assessment in the experi-
mental and control wards.
Baseline assessment will be performed by evaluating
the quality of end-of-life care in each pair of rando-
mized wards for all eligible cancer deaths in the 3
months before the randomization date (months -1 to -3
in Figure 2).
T h eL C P - IP r o g r a mw i l lb ei m p l e m e n t e di nt h e
experimental ward by the PCU (t1 to t6, Figure 2). The
LCP-I Program has a duration of 6 months from
the beginning of the intensive training (months 1-6 in
the figure). No intervention will be implemented in the
control ward until the end of the evaluation.
Effectiveness assessment (t7 to t12, Figure 2) will be
performed by evaluating the quality of end-of-life care
in each pair of randomized wards for all eligible cancer
deaths occurring in the six months after the conclusion
of the LCP-I Program in the experimental ward (months
7 to 12 in Figure 2).
End-points
Primary and secondary end-points will be evaluated
using the same procedure for all eligible cancer deaths,
in the baseline and in the effectiveness assessment.
The primary end-point of this trial is the overall qual-
ity of end-of-life care provided on the ward to dying
cancer patients and their families. The quality of end-of-
life care will be assessed using the Global Scale of the
Italian version of the Toolkit “After-death Bereaved
Family Member Interview“ [19,20]. The Toolkit is a
semi-structured interview with the nonprofessional care-
giver closest to the dying patient during the last days of
life in hospital. The interview is focused on the patient’s
last week of life (or less for patients with shorter hospi-
tal stays) and on care provided to the caregivers before
and after the patients’ death.
The secondary aims will be assessed through an analy-
sis of:
1. other six scales from the Toolkit “After-death
Bereaved Family Member Interview”.
a. Informing and promoting shared decision-
making
b. Encouraging advance care planning
c. Focus on individual
d. Attending to the emotional and spiritual needs
of the family
e. Providing coordination of care
f. Supporting the self-efficacy of the family
2. Symptom scales from the Italian version of
VOICES [21]
a. Pain
b. Breathlessness
c. Nausea and vomiting
3. Diagnostic and therapeutic procedures effectively
performed during the last 3 days of life
4. The outcome of an interview with the GPs of
patients who died on the wards and who are eligible
for the assessment
Furthermore, the evaluation of two leaflets included in
the LCP-I Program and delivered to family members
after the patient’s death is foreseen:
a. “Some useful information”, a leaflet delivered
t ot h ef a m i l ym e m b e r si m m e d i a t e l ya f t e r
patient’s death.
b. “Facing the loss” a leaflet delivered to bereaved
family members during a meeting after the
patient’s death.
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Figure 2 Design of the assesment procedures.
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families of patients hospitalized in the experimental
wards.
Eligibility criteria
Ward level
The inclusion criteria for each medical ward are:
￿ classified in the regional records as “Medical”,
“General Medical” or “Internal Medical";
￿ at least 25 cancer deaths on the ward per year.
The data can be estimated from a review of deaths
occurring on the ward over a minimum 6 month
period during the two years preceding the start of
the trial
￿ consent from the Hospital Management to partici-
pate to the trial
￿ consent from the Head of the Medical Ward to
participate to the trial
￿ consent from an expert and skills-trained PCU to
implement the LCP-I Program
Exclusion criteria:
￿ if in the same hospital another Medical Ward has
already been randomly selected to participate in the
research program (regardless of which arm was
randomized).
Individual level
For the two assessment periods (baseline and effective-
ness assessment) all cancer patients deceased in the
ward during the evaluation period will be considered
eligible. ICD- IX criteria will be used to identify cases
from the original death certificate. If the patient was a
relative of a doctor or a nurse working in the hospital
where the ward is located the patient will be considered
ineligible.
Procedures of assessment (Figure 3)
Primary and secondary end-points will be evaluated for
all eligible cancer deaths as follows:
1. Identification of eligible cancer deaths from the
ward: the cancer deaths in the ward will be identified
through the hospital’s deaths documentation (which lists
all deaths regardless of cause). Cancer deaths will be
identified by the International Classification of Diseases-
Ninth Revision (ICD-IX) criteria, applied to the causes
of death as reported in the death certificate of the Ita-
lian National Institute of Statistics (ISTAT).
2. Access to medical and nursing documentation
for the assessment of care procedure
3. Assessment of care procedures
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Figure 3 Procedures of assesment for the eligible population.
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Page 4 of 104. GP identification: name, address and telephone
number of the GPs will be obtained by medical docu-
mentation. However, all information are available in the
Regional Health records.
5. Caregiver identification: information regarding the
patients’ principal caregiver (name, relationship, address
and telephone number), as reported in the medical doc-
umentation, must be acquired. The principal caregiver is
the person who was closest to the patient during his/her
last week of life in hospital. It can be a family member
(most frequent) or a friend. If the patient had no care-
giver, the interview cannot be performed and the cir-
cumstances should be described in detail.
6. Letter to GPs: an official letter, signed by the
Regional Coordinator, des c r i b i n gt h es u r v e ya n d
announcing the telephone interview is sent to the
deceased’ GPs.
7. GPs telephone Interview: this must take place
within 4 months of the patients death and focuses on
two aspects:
◦ communication between ward staff and GPs
◦ confirmation or integration of information
regarding the patient’s caregiver (name, relation-
ship, address and telephone number).
8. Final Caregiver identification: obtained from two
main sources: medical documentation and/or patients’
GPs.
9. Caregiver Letter: an official letter, signed by the
Regional Coordinator, introducing the study and
announcing the telephone interview is sent to the
caregiver.
10. Phone contact with caregiver: it occurs 4-5 days
after the letter is sent out. The interviewer refers to the
contents of the letter and invites the caregiver to partici-
pate in an interview at a location of their choice.
11. Caregiver Interview: the Caregiver Interview
must take place between 2 and 4 months after the
patients’ death. it should be a face to face interview in a
location chosen by the caregiver. Only in exceptional
cases where the caregiver is unable to attend the face to
face interview (i.e. the caregiver lives in inaccessible
location) then the interview may be conducted by
phone. When the caregiver is obviously distressed and
unable to complete the interview, priority should be
given to the section of the Toolkit relative to the overall
evaluation (the 6 summary questions).
Randomisation
Randomization is centralized at the Trial Center of the
National Cancer Research Institute (IST) of Genoa. The
Regional Coordinators contact the IST Center for
the randomization of coupled wards. Randomization
lists for each region participating in the trial will be
compiled by the Trial Center. The randomization will
be carried out for pairs of wards. The sequence of each
list will be defined by blocked 1:1 allocation. The rando-
mization of the wards will be conducted by the Regional
Coordinators by telephone or fax.
For each request, the trial center:
￿ verifies the eligibility of the coupled wards
￿ assigns a numerical code to the two wards
￿ records the allocation of the wards
The LCP-I Program
The LCP-I Program is a continuous quality Improve-
ment Program of end-of-life care implemented by a Pal-
liative Care Unit (PCU) in a hospital Medical Ward.
The Program is articulated in 10 steps.
Step 1-3: Development of the implementation project on
the ward
￿ Step 1: Establishing the project - preparing the
environment
◦ Identify and describe the characteristics of the
ward
◦ Identify and describe the characteristics of the
PCU
◦ Obtain consent from the subjects involved
◦ Present the general outlines of the LCP-I Pro-
gram to the ward staff
◦ Outline the LCP-I Program on the ward
◦ Begin the approval procedure for the training
program
◦ Register the Project at the National Center for
LCP-I
￿ Step 2: Developing the Documentation
◦ Acquire educational materials for training
◦ Prepare the necessary documentation for the
ward
￿ Step 3: Base review - Retrospective evaluation
of variances related to end of life care on the
ward
◦ Review the medical documentation of the
patients who died on the ward
◦ Investigate the variances with the ward staff
Step 4-8: Implementation of the Program on the ward
The implementation of the LCP-I Program, following an
intensive training phase, revolves around the introduction
of the LCP-I medical chart and other specific documenta-
tion for patients who have been assessed by a multi-
professional team to be approaching the end of their life.
The LCP-I documentation provides recommendations on
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Page 5 of 10different aspects of care including comfort measures,
anticipatory prescription of medication and the assessment
of not appropriate medical and nursing interventions. It
also provides guidance for the psychological and spiritual
support of patients and their families. The LCP-I docu-
mentation allows the monitoring of results and supports
the implementation of audit procedures.
￿ Step 4: Induction of the Program. Intensive
Education Program (duration less than a month)
◦ 3 modules of 4 hours (12 hours total) repeated
twice to allow the participation of all clinical
ward staff (doctors and nurses).
￿ Step 5: Clinical implementation of the LCP-I
documentation. Intensive support to the ward
staff (6 weeks)
◦ the ward staff, closely supported (coaching, tel-
ephone and direct guidance, discussion of clinical
cases) by the PCU team overseeing the imple-
mentation process, starts using the LCP-I docu-
mentation for dying patients.
￿ Step 6: Semi-intensive support to the ward staff
(6 weeks)
◦ the ward staff, accompanied by the PCU team
overseeing the implementation process, learns to
use the LCP-I documentation as standard proce-
dure for dying patients.C l i n i c a la u d i t sa r e
planned for difficult cases.
￿ Step 7: Evaluation and further Training (end of
the 4° month)
◦ the PCU team evaluates the outcome of the
preliminary steps with the aim of developing an
a p p r o p r i a t et r a i n i n gs t r a t e g yf o rt h ew a r ds t a f f
during the subsequent stages of the implementa-
tion process.
￿ Step 8: Consolidation phase (2 months)
◦ the LCP-I documentation is established in the
ward as an indicator of the quality of end of life
care for all dying patients. The PCU team sup-
ports the ward staff using the most suitable tools
for consolidation of the changes introduced by
the LCP-I Program.
Step 9-10: sustainability of high standards of quality of
end of life care on the ward
If the ward staff evaluates positively the use of the LCP-I
documentation for dying patients, the PCU responsible
for the implementation process, actively supports the
d e v e l o p m e n to fas u s t a i n a b l ep o l i c yf o rt h ew a r da n d
hospital management. The strategy revolves around the
institutionalization of the LCP-I documentation. A feasi-
ble approach is the development of a care strategy that
guarantees and documents the maintenance of high
standards in the quality of end of life care provided.
￿ Step 9: Initiation of a strategy for sustainability
◦ the LCP-I is established as routine procedure
on the ward and in the hospital
◦ d e v e l o pa ne n d - o f - l i f ec a r es t r a t e g yf o rt h e
ward.
￿ Step 10: Regional and national strategy
◦ use the outcome of the trial study to stimulate
discussions at a regional and national level
regarding issues linked to the quality of end-of-
life care
Statistical methods
Primary end-point
The primary end-point of this trial is the overall quality
of the end-of-life care provided by the ward staff to dying
cancer patients and their families. The quality of end-of-
life care will be assessed using the Global Scale of the
“Toolkit After-death Bereaved Family Member Interview“.
The Global Scale of the Toolkit is a combination of
6 items that are evaluated at the end of the interview on
a0 - 1 0s c a l e( s e ep a g e1 5o ft h eT o o l k i t ) .T h es c o r e so f
the 6 items are added up and linearized on a 0-100
scale where 0 equals poor quality and 100 equals high
quality of care. Where answers are missing for one or
more of the 6 items, the score is estimated for the item
for which valid answers are available. To calculate the
score on the Global Scale a minimum of 4 valid answers
out of 6 are necessary.
The quality of the end-of-life care provided to dying
patients, assessed with the Global Scale of the Toolkit, is
expressed on a 0-100 scale where 0 equals poor quality
and 100 equals excellent quality of care.
Sample size
An absolute increase of average scores on the Global
Scale of the Toolkit of 10-15 points (in experimental
wards compared to control wards) can be considered the
minimum difference of clinical interest which justifies
the implementation of the LCP -I Program. This increase,
based on the results of the pilot study corresponds to an
Effect Size (ES) of about 0.4. In order to estimate sample
size in a cluster trial, along with Type I and II errors, two
elements are essential: the intra-cluster correlation coeffi-
cient and the average size of the cluster (number of clus-
ter deaths) [22]. So, for this trial:
◦ the intraclass correlation coefficient can be esti-
mated between 0.01 and 0.05 [23]
◦ according to the review of cancer deaths on the
Medical Wards potentially involved, we can expect
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of the assessment ranging between 15 and 20.
◦ it is foreseen that the regions participating will be
able to randomize 10 pairs of Medical Wards (20
clusters overall).
Data in the Table 1 intersect three ICC scenarios (from
0.01 to 0.1) with 4 scenarios of average cluster size (from
10 to 25). In the corresponding sections the total cluster
required to achieve a cluster trial with a coefficient of
80% are reported to a two-tailed alpha error of 0.5 and an
a hypothetical ES of 0.4. Table 1 reports different sample
size scenarios necessary to detect an ES of 0.4 with alpha
= 0.05 and a power of 80% conditional to the hypothe-
sized levels of ICC (from 0.01 to 0.10) and average size of
the clusters (from 10 to 25). According to the informa-
tion reported in the previous paragraphs, it seems realis-
tic to assume that the study is feasible with a total
number of clusters no greater than 20 [22].
Statistical analysis
The centers and patients characteristics will be reported as
mean and standard deviation (SD) or frequency and per-
centage, respectively, for continuous and categorical vari-
ables. The distribution of variables of clusters allocated as
experimental or control wards will be compared with the
t-Student test or one way ANOVA (for ordinal or continu-
ous variables) and with the Pearson Chi-square (for binary
or nominal variables).
The assessment of the primary end-point will take into
account the clustered design of the trial through the use of
hierarchical linear models [24,25]. These models will be
adjusted for the average level of quality of care provided to
the baseline assessment. The results will be expressed in
terms of beta coefficients of regression or in estimated
marginal means, 95% Confidence Intervals (IC 95% CI)
and level of significance. P-value < 0.05 will be considered
statistically significant. The same approach will be used for
the assessment of the continuous secondary end-points
where there are continual variables. For the assessment of
categorical secondary end-points with categorical vari-
ables, the hierarchical logistical model will be used.
All the analysis will be conducted using the SAS Statis-
tical Package Release 9.1 (SAS Institute, Cary, NC, USA).
Ethical issues
Clinical guidelines for the care of dying patients are
available but research promoting the acquisition of valid
knowledge in this area is still lacking. This can be attrib-
uted, in part, to the ethical issues which inevitably arise
when carrying out research in this field. The vulnerabil-
ity of the individuals involved, often aggravated by phy-
sical and psychological conditions related to elevated
levels of stress, poses serious ethical dilemmas. In addi-
tion, dying patients are often unaware of the diagnosis
or the gravity of their illness or may be incapacitated.
These circumstances, plus difficulties encountered in
obtaining valid patient informed consent, constitute bar-
riers which discourage research in the end-of-life care
context.
Only a fraction of the above mentioned barriers affects
this study. The LCP-I Program is not aimed at increas-
ing knowledge about end-of-life care but at improving
the quality of end-of-life care delivered in hospitals. The
LCP-I Program introduces in a medical ward effective
procedures currently practiced in hospices worldwide
onto the hospital ward. Hence, this trial is not aimed at
consolidating scientific knowledge regarding the clinical
and non-clinical recommendations contained in the Pro-
gram but rather at assessing the effectiveness of the
entire Program as a tool for improving care delivery. In
other words, the aim of this study is to assess if the Pro-
gram succeeds in its intent of improving the quality of
end-of-life care delivery on the hospital ward by shifting
the attitudes and actions of clinical staff towards better
care practices. The study population is the clinical ward
staff and not the patients: the involvement of patients
and their families is only necessary to verify the efficacy
of the change toward a better quality of care delivery.
It is now widely recognized that healthcare institutions,
and the medical workforce, have a moral obligation to
promote and support interventions for improving medi-
cal practices. Although quality improvement activities
share some of the characteristics of clinical research and
the boundary between these two areas often overlap (in
both cases the effectiveness of an intervention is mea-
sured) there are, nonetheless, fundamental differences
between the two areas that justify the adoption of differ-
ent procedures for guaranteeing ethical conduct. With
consideration to these differences (the minimal risk for
the patients involved in quality improvement programs,
the demonstrable and immediate benefit to those directly
concerned, the introduction of existing evidence-based
practices, the flexible and not rigidly formalized proto-
cols, the necessity and obligation for health care institu-
tions to improve the of the quality of care practices, the
indirect use of personal data, the absence of sponsors,
the clear public interest, etc.), the related international
literature highlights the inadequacy of applying the strict
Table 1 Total number of clusters required according to
different cluster sizes and ICC (ES = 0.4, alpha = 0.05,
power = 0.80)
Average size of the clusters
Intraclass Correlation Coefficient 10 15 20 25
0.01 22 16 12 10
0.05 30 24 20 18
0.10 38 32 30 28
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informed consent, to quality-improvement programs,
and favors the adoption of different informative/consent
procedures and, where possible, a responsible and
informed participation of patients [26].
For the above mentioned reasons, it is evident that it
is not feasible to request informed consent from the
patients as, in this study, the target population is the
clinical staff. However, in order to guarantee confidenti-
ality to patients whose data could be used as indicators
to verify the validity of the Program, certain procedures
are recommended:
￿ the ethics committee is required not only to
express an opinion on the study, but also to carry
out monitoring activities. More precisely, every
3 months the Scientific Coordinator will send to the
Ethical Committee of the National Cancer Research
Institute of Genoa and to the Ethical Committees of
each trust involved in the trial a detailed progress
report highlighting all variances, in particular with
regards to the relations with the family. For any
further clarification, each Ethical Committee can
request the Scientific Coordinator’s participation.
As far as ethical issues regarding the proper handling
of data is concerned it is necessary to distinguish two
different phases of the trial:
1. collection and elaboration of data in the
patients’ medical documentation
2. contact and interview with the caregivers
Regarding collection and elaboration of data from
patients’ medical documentation:
￿ the processing of data included in medical docu-
mentation is considered of significant public interest,
to that purpose, in agreement with Articles 20 and
21 of the Italian Confidentiality Laws, it is accessible
to the National Health Service and other Public
Health organizations for the planning, management,
monitoring and evaluation of healthcare;
￿ in theory the evaluation could be subject to
informed consent of the terminal cancer patients
(patients who might die of cancer). In fact, the
patients involved in the Program evaluation, who are
nearly always incapable of giving valid consent, are
identified after death (as cancer deaths), regardless
of whether they were hospitalized in a ward where it
LCP-I Program was implemented;
￿ in all cases, where the patients are competent and
aware of their health status (parameters previously
assessed independently in the LCP-I Program) and
where there is considered no risk to the patient, the
clinical ward staff will be trained to deliver informa-
tion to the patient and to ask them the consent to
the use of personal data. This procedure will be
recorded in the medical records;
￿ during the study and in subsequent publications,
any personal data will be disaggregated and made
anonymous.
Regarding contact with the caregivers, the initial con-
tact will be made through a personal letter which
includes detailed information and requests their permis-
sion to be contacted by telephone. The caregiver will be
contacted by phone after at least 3 days and will be
invited to participate in the interview. The interview will
be conducted by specifically trained staff.
This procedure has been used successfully in the
ISDOC survey [21], with very satisfactory results:
￿ sampling of 2,000 cancer deaths in 30 Italian Local
Healthcare Authorities’ areas.
￿ caregiver identification in 95% of cases (N = 1900)
￿ realization of 1271 valid interviews (64% of the
sample).
￿ reasons for non-completion of the interviews: no
caregiver identified (5%), refusal (20%), caregiver not
contactable (8%), other (3%).
As described in a published article [21], the interviewers
did not encounter particular resistance in the realization
of the interviews. Many caregivers found the letter respect-
ful of their circumstances and the information provided
about the procedures and the objectives of the study rela-
tively comprehensive. In only one case (out of 1900), a
cancer patient’s daughter complained that a letter, specify-
ing the cause of her father’s death, had been sent to her
mother who had not been aware of the nature of her hus-
band illness. Following this observation, the cause of death
is not specified in the letter used in this study.
In conclusion, the cluster design of the study and the
randomization of wards to receive or not LCP-I Program is
necessary for a scientifically based assessment of the effec-
tiveness of the Program. However, to ensure that all the
wards involved can benefit from the improvement brought
by the Program, unless it proves to be not effective, at the
conclusion of the trial the implementation of the LCP-I
Program will be proposed also to the control wards.
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Although it is now widely shared that clinical practice
should be, wherever possible, evidence-based, programs
to improve the quality of care are often implemented
without an evaluation of their effectiveness [27].
Assessing these interventions is a challenge for their
complexity, due to the presence of different types of
components, activities, interventions and outcomes to
be achieved [27], and for specificity of the context of
development and application.
The “Medical Research Council’sF r a m e w o r kf o rt h e
Development and Evaluation of Complex Interventions
to Improve Health (MRC Framework) [28] is a promis-
ing and innovative approach aimed at providing a robust
methodological basis to the evaluation of complex inter-
ventions. The MRC Framework has been used to
develop and evaluate different treatments, services or
public health interventions, including programs to
improve the quality of care [29-31].
As for as the evaluation of drugs, the MRC Frame-
work is divided into five stages, from “pre-clinical”
Phase to Phase IV. Each phase suggests the uses of
appropriate quantitative and/or qualitative methodolo-
gies for the specific objectives of the phases, and
requires a specific study design taking into account the
theoretical basis, any evidence on the issue and the con-
text’s specificity [29]. More recently, it has been under-
lined that the MRC Framework is flexible and adaptable
approach, and the five phases has not to be clearly sepa-
rated [32]. For example, “pre-clinical phase” and phases
I and II may be part of a unique approach that includes
the study and understanding of the problem and con-
text, the construction of models of intervention and the
feasibility of assessment [32].
The LCP Program can be defined as a complex inter-
vention to improve the quality of end-of-life care inde-
pendently of diagnosis and place of death. The results
from qualitative studies [33-35] and from experimental
assessments in non-randomized trials [36,37] seem to
suggest that the LCP Program can improve significantly,
and over long-term, the quality of end-of-life care deliv-
ery in hospitals and other care settings. According to
the MRC Framework, published research on the LCP
completed the first three phases, from preclinical phases
to phase II.
This study can be interpreted as a Phase III trial
according to the MRC framework. In this study, the
effectiveness of a fully defined intervention is assessed
by comparing the distribution of the endpoints in the
experimental arm and in the control arm. Although not
all dying patients will be supported by the LCP Program,
the assessment is planned on the whole sample of
patients deceased in the experimental ward and in the
correspondent control ward.
Cluster trial are often used for assessing interventions
directed at a hospital team [22]. The validity of this pro-
tocol is supported by the results of a recent Cochrane
Review [38] on the effectiveness of end-of-life pathways.
The review did not find any randomised controlled
trials, quasi-randomised trial or high quality controlled
before and after studies, to include in the analysis. The
authors concluded that there is a lack of evidence sup-
porting such practice [38], and recommend the use of
cluster randomised trials as the most effective study
design in evaluating this approach [38].
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